Related Experiment Video
Updated: Aug 1, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Role of phosphoinositide 3-kinase in cardiac function and heart failure
Sathyamangla V Naga Prasad1, Cinzia Perrino, Howard A Rockman
1Department of Medicine, Cell Biology and Genetics, Duke University Medical Center, Durham, NC 27710, USA.
Abstract:
Phosphoinositide 3-kinase (PI3K) belongs to a conserved family of lipid kinases that regulate many critical functions in the cell by generating 3'-phosphorylated phosphatidylinositols. Although PI3K has been the focus of intense study in various biologic processes including apoptosis, metastasis, and neuronal differentiation, it is only recently that the focus has shifted to understanding the role of PI3K in cardiac function, hypertrophy, and heart failure. This article reviews the role of PI3K in regulating cardiac growth, contractility, beta-adrenergic receptor function, and hypertrophy, as well as possible novel therapeutic strategies in the treatment of heart failure.
More Related Videos
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
08:07Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
Published on: July 26, 2019
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
IP3/DAG Signaling Pathway
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy III: Hypertrophic Cardiomyopathy